scholarly journals Are data from general practices suitable for survival analyses in the field of breast cancer? A retrospective study conducted in the United Kingdom, France and Germany

2019 ◽  
Author(s):  
Louis Jacob ◽  
Matthias Kalder ◽  
Gabriele Haas ◽  
Karel Kostev
Keyword(s):  
Breast Cancer ◽  
United Kingdom ◽  
Retrospective Study ◽  
Survival Analyses ◽  
The United Kingdom ◽  
General Practices

A multicenter retrospective study into endogenous causes of uveitis in cats in the United Kingdom: Ninety two cases

2021 ◽  
Author(s):  
Michaela L. Wegg ◽  
Emily C. Jeanes ◽  
Danica Pollard ◽  
Lorraine Fleming ◽  
Charlotte Dawson
Keyword(s):  
United Kingdom ◽  
Retrospective Study ◽  
The United Kingdom

A Comparison of the Information Needs of Women Newly Diagnosed With Breast Cancer in Malaysia and the United Kingdom

2005 ◽  
Vol 28 (2) ◽  
pp. 132???140 ◽  
Author(s):  
Raja Lexshimi Raja Gopal ◽  
Kinta Beaver ◽  
Tony Barnett ◽  
Nik Safiah Nik Ismail
Keyword(s):  
Breast Cancer ◽  
United Kingdom ◽  
Information Needs ◽  
Newly Diagnosed ◽  
The United Kingdom

Allergic Contact Cheilitis in the United Kingdom: A Retrospective Study

Dermatitis ◽  
2003 ◽  
Vol 14 (02) ◽  
pp. 075
Author(s):  
Roland M. Strauss ◽  
David I. Orton
Keyword(s):  
United Kingdom ◽  
Retrospective Study ◽  
The United Kingdom ◽  
Allergic Contact

Breast malignancy

2021 ◽  
pp. 1025-1052
Author(s):  
Kieran Horgan ◽  
Barbara Dall ◽  
Rebecca Millican-Slater ◽  
Russell Bramhall ◽  
Fiona MacNeill ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United Kingdom ◽  
Cancer Diagnosis ◽  
Invasive Breast Cancer ◽  
Breast Cancer Diagnosis ◽  
Developed Countries ◽  
Western World ◽  
Breast Malignancy ◽  
The United Kingdom

Breast cancer is the commonest cancer to affect women in developed countries and is increasing in frequency in the Western world. Approximately 50,000 women and 400 men are diagnosed with breast cancer in the United Kingdom each year. Eighty per cent of these individuals will survive for at least 5 years after diagnosis. In 2012, 11,762 women died of breast cancer in the United Kingdom. Age-standardized rates of new invasive breast cancer diagnosis have increased from 75 to 126 per 100,000 population in the United Kingdom between 1977 and 2010.

scholarly journals Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom

2005 ◽  
Vol 94 (1) ◽  
pp. 30-35 ◽  
Author(s):  
J E Lester ◽  
D Dodwell ◽  
J M Horsman ◽  
S Mori ◽  
R E Coleman
Keyword(s):  
Breast Cancer ◽  
United Kingdom ◽  
Bone Loss ◽  
Current Management ◽  
The United Kingdom

913 Information needs of men with breast cancer in the United Kingdom

2003 ◽  
Vol 1 (5) ◽  
pp. S275
Author(s):  
B. Williams ◽  
K. Brain ◽  
R. Iredale ◽  
J. Gray ◽  
E. France
Keyword(s):  
Breast Cancer ◽  
United Kingdom ◽  
Information Needs ◽  
The United Kingdom

A retrospective study of inflammatory breast cancer patients from seven hospitals in the United Kingdom.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11062-e11062
Author(s):  
Saeed Rafii ◽  
Christopher John Poole ◽  
Adele Francis ◽  
Shalini Chaudhri ◽  
Daniel Rea
Keyword(s):  
Breast Cancer ◽  
United Kingdom ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Inflammatory Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Patients ◽  
The United Kingdom ◽  
Her 2 ◽  
Clinical Records

e11062 Background: Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer characterised by rapidly progressive breast erythema, pain and tenderness, oedema and paeu d’orange. It is estimated that between 1-4 % of all newly diagnosed breast cancer patients in the United Kingdom have IBC. Methods: We retrospectively identified 51 patients who were treated for IBC at 7 hospitals in the West midlands area of the United Kingdom between 1997 and 2011. Data including patients’ demographics, clinical, radiological and histopathological characteristics were collected from electronic clinical records. The test for HER-2 over-expression was not carried out routinely before 2002, therefore HER-2 status of such patients were assessed retrospectively on the archived tissues. A cox regression analysis was used for statistical assessment of survival and prognostic factors. Results: Median age at diagnosis was 55 years (range 34-83 yrs). Median overall (OS) and progression free survival (PFS) were 32 months (range 7-97 months) and 27 months (range 2-53 months) respectively. The 3–year survival rate for the entire cohort was 32%. Majority of patients were ER and HER-2 positive (49% and 52% respectively). The rate of complete pathological response (pCR) after neoadjuvant chemotherapy was 14%. All cases who had achieved pCR were HER-2 positive who had received anti HER-2 treatment during the neoadjuvant chemotherapy. The OS for the HER-2 positive patients with pCR was not statistically different from the whole cohort (49 vs 32 months, p=0.09) or from the patients with residual disease (49 vs 26 months, p=0.13). Although the triple negative IBC patients consisted 20% of the cohort, no patients in this group had achieved pCR. The OS and PFS for the triple negative patients were 20 and 14 months respectively. Although the rate of pCR was higher in patients treated with taxane compared to those treated with anthracycline containing chemotherapy (35% vs 7%), there was no significant difference in OS between either of these regimens (29 vs 27 months). Conclusions: HER-2 positive IBC patients had higher rate of achieving pCR after neo-adjuvant anti HER-2 therapy. However higher rate of pCR did not improve the OS.

Sign in / Sign up

Export Citation Format

Share Document